TRAIL, also called Apo‐2 ligand (Apo‐2L), belongs to the tumor necrosis factor family that preferentially triggers apoptosis in various tumor cells.42 It has drawn major attention for its potential utilization in cancer therapy as an effective anticancer tool that causes almost no cytotoxicity to normal cells. Here, TNFSF10 is linked to neoplasm.